ライフサイエンスコーパス: amlexanox

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 However, amlexanox, a compound that is known to attenuate actin s

2 an anti-allergic and anti-inflammatory drug, amlexanox (AMX).

3 Here we report that amlexanox, an approved small-molecule therapeutic presen

4 S100A13 binds the anti-inflammatory compound amlexanox and FGF-1 is involved in inflammation, we exam

5 Amlexanox binds S100A13 and inhibits the release of fibr

6 ast, the inhibition of cell proliferation by amlexanox correlates with the inhibition of cyclin D1 ex

7 ll migration and proliferation, and although amlexanox does not induce either the down-regulation of

8 Treatment of obese mice with amlexanox elevates energy expenditure through increased

9 dy demonstrates the potential of repurposing amlexanox for the treatment of patients with RDEB harbor

10 Amlexanox increased COL7A1 transcript and the phosphoryl

11 x to modify the cytoskeleton and report that amlexanox induces a dramatic reduction in the presence o

12 Correspondingly, amlexanox induces the complete and reversible non-apopto

13 onsense-mediated mRNA decay, suggesting that amlexanox inhibits nonsense-mediated mRNA decay in cells

14 Because of its record of safety in patients, amlexanox may be an interesting candidate for clinical e

15 to partially rescue cells from the effect of amlexanox on both the actin cytoskeleton and cell migrat

16 in mediating the acute metabolic benefits of amlexanox on glucose metabolism, and point to a new ther

17 in inflammation, we examined the effects of amlexanox on the release of FGF-1 and p40 Syn-1 in respo

18 ses by treatment of obese mice with the drug amlexanox reversed obesity-induced catecholamine resista

19 ation with shRNA or small-molecule inhibitor amlexanox selectively inhibited the viability of NSCLC c

20 Last, the ability of amlexanox to inhibit FGF1 release is reversible and corr

21 the cytoskeleton, we examined the ability of amlexanox to modify the cytoskeleton and report that aml

22 cute inhibition of IKK-epsilon and TBK1 with amlexanox treatment increases cAMP levels in subcutaneou

23 We report that while amlexanox was able to repress the heat shock-induced rel

24 Here the FDA-approved drug amlexanox was tested for its ability to read-through PTC

25 In vivo studies revealed that combining amlexanox with MEK inhibitor AZD6244 significantly inhib

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。